Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of Directors
Senior management
Our history
Research and development
Technology platform
Therapeutic areas
Pipeline
Scientific papers and presentations
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Financial calendar
Corporate governance
Corporate governance statements
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
ESG
Email alerts
Media
News and announcements
Image library
Glossary
Email alerts
Careers
Life at Nykode
Meet us
Open positions
Search
Media
News and Announcements
Newest first
Oldest first
Announcements
News
Search
Reset
10/10/2018
VACCIBODY UPDATES ON CANCER NEOANTIGEN PHASE I/IIA CLINICAL TRIAL: FIRST 10 PATIENTS ENROLLED, AND VACCINATIONS STARTED.
26/09/2018
Positive results from the 6-months Interim analysis of the phase IIa clinical study in high grade cervical dysplasia provides Proof-of-Concept for Vaccibody’s immunotherapy platform.
20/09/2018
Vaccibody announces clinical collaboration agreement with Nektar Therapeutics for evaluation of Vaccibody’s personalized cancer neoantigen vaccine in combination with Nektar’s CD-122-biased agonist, NKTR-214
24/08/2018
QUARTERLY REPORT – 2018 Q2
14/05/2018
QUARTERLY REPORT – 2018 Q1
Pages:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer